Keforal (Cefalexin)

Cefalexin works by binding to bacterial penicillin‑binding proteins, inhibiting the synthesis of the peptidoglycan layer of the cell wall. This disruption weakens the wall, leading to osmotic lysis and death of susceptible Gram‑positive and some Gram‑negative bacteria.

The dosage of Keforal is determined by the prescribing healthcare professional based on the type and severity of infection, patient age, weight, and renal function. Patients should follow the exact regimen provided by their prescriber and not adjust the dose on their own.

Safety data for cefalexin during pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant. Pregnant or nursing patients should discuss use with their healthcare provider.

To order Keforal, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and necessary import documentation.

Keforal (cef alexin) is a cephalosporin, offering a broader spectrum against certain Gram‑positive organisms compared with penicillins like amoxicillin, and it is generally more resistant to beta‑lactamase degradation. However, amoxicillin may be preferred for some beta‑lactamase‑producing strains, and choice depends on susceptibility patterns and clinical context.

Keforal tablets should be stored at ambient temperature, below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Keforal is administered orally, usually with a full glass of water. It may be taken with or without food, but taking it with food can reduce gastrointestinal upset. Patients should swallow tablets whole and not crush or chew them unless instructed otherwise.

Serious risks include severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome or toxic epidermal necrolysis, and Clostridioides difficile‑associated colitis. Patients should seek immediate medical attention if they develop rash, fever, persistent diarrhea, or signs of an allergic reaction.

Keforal should not be used by individuals with a known hypersensitivity to cefalexin, other cephalosporins, or penicillins. It is also contraindicated in patients who have experienced severe allergic reactions to beta‑lactam antibiotics. Clinicians should evaluate each patient’s medical history before prescribing.